Dualsystems Biotech Announces Profiling Service for Reducing Drug Development Time and Overall Development Costs
Find Out More
A fee-based drug profiling service designed to characterize the mechanism of action and identify off-target effects and novel targets for drugs under development is now available from Dualsystems Biotech AG. This early in-depth profiling of drug candidates helps shorten development time, lowers overall development costs, and results in drugs with a better safety profiles. To ensure reliable results, the service utilizes the company’s CaptiVate™ platform.
The profiling process takes approximately 4 to 6 months and includes compound derivatization and toxicity testing, screening against two cDNA libraries, identification of primary interactors, and re-testing of interactors to ensure compound dependency. Compound-dependent interactions of selected target proteins may be further characterized using competition assays, in vitro binding assays, and mammalian three-hybrid assays. The service is capable of profiling several protein classes, including kinases and nuclear receptors. The company does not retain any claim on results or associated intellectual property.
clinical diagnostics
A fee-based drug profiling service designed to characterize the mechanism of action and identify off-target effects and novel targets for drugs under development is now available from Dualsystems Biotech AG. This early in-depth profiling of drug candidates helps shorten development time, lowers overall development costs, and results in drugs with a better safety profiles. To ensure reliable results, the service utilizes the company’s CaptiVate™ platform.
